Document is current
Any future updates will be listed below
-
Authors
Rubbert-Roth, Andrea https://orcid.org/0000-0002-9016-2833
Kakehasi, Adriana M.
Takeuchi, Tsutomu
Schmalzing, Marc
Palac, Hannah
Coombs, Derek
Liu, Jianzhong
Anyanwu, Samuel I.
Lippe, Ralph
Curtis, Jeffrey R.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02706873 at ClinicalTrials.govnct02675426 at ClinicalTrials.govDocuments that mention this clinical trial
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2023-223916
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (Post-results)
https://doi.org/10.1136/annrheumdis-2020-218510
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
THU0192 UPADACITINIB MONOTHERAPY IMPROVES PATIENT-REPORTED OUTCOMES IN METHOTREXATE-NAÏVE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM SELECT-EARLY
https://doi.org/10.1136/annrheumdis-2019-eular.978
nct02629159 at ClinicalTrials.govDocuments that mention this clinical trial
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
https://doi.org/10.1007/s12325-021-01930-4
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials
https://doi.org/10.1007/s40744-022-00483-4
SAT0254 Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: results from select-next
https://doi.org/10.1136/annrheumdis-2018-eular.1202
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2023-223916
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (Post-results)
https://doi.org/10.1136/annrheumdis-2020-218510
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
nct02706951 at ClinicalTrials.govDocuments that mention this clinical trial
Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy
https://doi.org/10.1136/rmdopen-2025-005521
Waiting for JAK inhibitor safety data
https://doi.org/10.1136/rmdopen-2022-002236
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
POS0639 BENEFIT–RISK ANALYSIS OF UPADACITINIB VERSUS ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGHER OR LOWER RISK OF CARDIOVASCULAR DISEASE
https://doi.org/10.1136/annrheumdis-2024-eular.1416
OP0225 EVALUATION OF RESPONSE TO ADJUVANTED RECOMBINANT ZOSTER VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB: RESULTS FROM A RANDOMIZED TRIAL SUB-STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.2386
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
https://doi.org/10.1007/s40744-024-00658-1
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
https://doi.org/10.1136/rmdopen-2023-004007
Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease
https://doi.org/10.1136/rmdopen-2024-005371
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
FRI0089 COMPARATIVE EFFICACY (ACR 20) OF TOCILIZUMAB TO OTHER TARGETED IMMUNE MODULATORS (TIM) FOR RHEUMATOID ARTHRITIS: A NETWORK META-ANALYSIS (NMA)
https://doi.org/10.1136/annrheumdis-2020-eular.532
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2020-218412
OP0020 IMMUNOGENICITY OF AN ADJUVANT RECOMBINANT ZOSTER VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB: 60-WEEK RESULTS FROM A RANDOMIZED SUBSTUDY
https://doi.org/10.1136/annrheumdis-2024-eular.763
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
https://doi.org/10.1136/annrheumdis-2019-215764
POS0643 ASSOCIATION OF EARLY REMISSION ON CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS: POST-HOC ANALYSIS OF DATA FROM THE SELECT-COMPARE STUDY
https://doi.org/10.1136/annrheumdis-2024-eular.1469
FRI0137 UPADACITINIB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM SELECT-COMPARE
https://doi.org/10.1136/annrheumdis-2019-eular.287
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2023-223916
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (Post-results)
https://doi.org/10.1136/annrheumdis-2020-218510
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
nct02706847 at ClinicalTrials.govDocuments that mention this clinical trial
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
https://doi.org/10.1007/s12325-021-01930-4
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
POS0847 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 260 WEEKS FROM THE SELECT-MONOTHERAPY STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.2423
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study
https://doi.org/10.1136/rmdopen-2024-005051
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2023-223916
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (Post-results)
https://doi.org/10.1136/annrheumdis-2020-218510
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
nct03086343 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND
https://doi.org/10.1136/rmdopen-2023-004037
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
https://doi.org/10.1136/rmdopen-2023-003918
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials
https://doi.org/10.1007/s40744-022-00483-4
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2023-223916
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (Post-results)
https://doi.org/10.1136/annrheumdis-2020-218510
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
SAT0255 Patient reported outcomes of upadacitinib: results from biologic inadequate responders (SELECT BEYOND PHASE III TRIAL)
https://doi.org/10.1136/annrheumdis-2018-eular.1254
nct03104400 at ClinicalTrials.govDocuments that mention this clinical trial
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study
https://doi.org/10.1007/s40744-024-00694-x
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2023-223916
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
nct03104374 at ClinicalTrials.govDocuments that mention this clinical trial
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
https://doi.org/10.1136/rmdopen-2021-001838
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
https://doi.org/10.1007/s40744-021-00379-9
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
POS0081 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.799
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
https://doi.org/10.1007/s40744-022-00499-w
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
https://doi.org/10.1007/s40744-022-00449-6
OP0061 DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2394
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
https://doi.org/10.1136/annrheumdis-2020-218870
POS1047 IMPACT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH INADEQUATE RESPONSE TO NON-BIOLOGIC OR BIOLOGIC DMARDs
https://doi.org/10.1136/annrheumdis-2021-eular.1633
POS0945 SUSTAINABILITY OF RESPONSE WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE PSORIATIC ARTHRITIS: WEEK 152 DATA FROM THE SELECT-PSA 1 AND SELECT-PSA 2 TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.1410
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
OP0233 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL INVOLVEMENT
https://doi.org/10.1136/annrheumdis-2021-eular.439
POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.2699
AB1090 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY INVOLVEMENT OF WEIGHT-BEARING JOINT REGIONS: A POST HOC SUBGROUP ANALYSIS OF THE PHASE 3, RANDOMIZED, SELECT-PSA 1 AND SELECT-PSA 2 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.3944
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
https://doi.org/10.1136/rmdopen-2021-002049
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
https://doi.org/10.1007/s40744-021-00410-z
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
nct03178487 at ClinicalTrials.govDocuments that mention this clinical trial
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
https://doi.org/10.1007/s40744-022-00449-6
OP0061 DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2394
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2 (Results)
https://doi.org/10.1136/annrheumdis-2020-218870
POS1047 IMPACT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH INADEQUATE RESPONSE TO NON-BIOLOGIC OR BIOLOGIC DMARDs
https://doi.org/10.1136/annrheumdis-2021-eular.1633
POS0945 SUSTAINABILITY OF RESPONSE WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE PSORIATIC ARTHRITIS: WEEK 152 DATA FROM THE SELECT-PSA 1 AND SELECT-PSA 2 TRIALS
https://doi.org/10.1136/annrheumdis-2024-eular.1410
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
OP0233 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL INVOLVEMENT
https://doi.org/10.1136/annrheumdis-2021-eular.439
POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.2699
AB1090 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY INVOLVEMENT OF WEIGHT-BEARING JOINT REGIONS: A POST HOC SUBGROUP ANALYSIS OF THE PHASE 3, RANDOMIZED, SELECT-PSA 1 AND SELECT-PSA 2 TRIALS
https://doi.org/10.1136/annrheumdis-2023-eular.3944
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
https://doi.org/10.1136/rmdopen-2021-002049
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
https://doi.org/10.1007/s40744-021-00410-z
POS1041 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC THERAPIES: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 2 STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.1897
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
nct04169373 at ClinicalTrials.govDocuments that mention this clinical trial
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
https://doi.org/10.1136/rmdopen-2022-002280
Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease
https://doi.org/10.1136/rmdopen-2024-005110
POS0905 ACHIEVEMENT OF PARTIAL REMISSION AND INACTIVE DISEASE IN UPADACITINIB-TREATED PATIENTS WITH ANKYLOSING SPONDYLITIS
https://doi.org/10.1136/annrheumdis-2021-eular.566
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
https://doi.org/10.1136/rmdopen-2022-002735
POS0907 EFFECT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND INADEQUATE RESPONSE TO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
https://doi.org/10.1136/annrheumdis-2021-eular.604
OP0061 DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2394
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2023-003392
OP0144 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 1-YEAR RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION
https://doi.org/10.1136/annrheumdis-2021-eular.473
POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.2699
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
https://doi.org/10.1136/rmdopen-2021-002049
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
Documents that mention this clinical trial
POS0306 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2022-eular.2518
POS0685 MONITORING PHYSICAL ACTIVITY OF PATIENTS WITH ANKYLOSING SPONDYLITIS IN THE SELECT-AXIS 2 PHASE 3 TRIAL: BASELINE USAGE AND ADHERENCE RESULTS FROM A WEARABLE DEVICE STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.517
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-023-00621-6
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
https://doi.org/10.1136/rmdopen-2022-002280
Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease
https://doi.org/10.1136/rmdopen-2024-005110
POS1111 TREATMENT WITH UPADACITINIB RESULTS IN THE INHIBITION OF A BROAD RANGE OF POTENTIALLY PATHOGENIC PATHWAYS IN NR-AXSPA AND BDMARD-IR AS PATIENTS: PROTEOMIC ANALYSIS FROM THE SELECT-AXIS 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2023-eular.3708
Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2
https://doi.org/10.1007/s40744-023-00550-4
POS1108 EFFICACY OF UPADACITINIB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN EARLY VERSUS ESTABLISHED DISEASE
https://doi.org/10.1136/annrheumdis-2023-eular.2123
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
https://doi.org/10.1136/ard-2022-222608
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis
https://doi.org/10.1007/s40744-023-00536-2
OP0061 DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2394
AB0947 EFFECT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND INADEQUATE RESPONSE TO BIOLOGIC THERAPY
https://doi.org/10.1136/annrheumdis-2023-eular.3918
OP0016 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2022-eular.2534
POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.2699
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
https://doi.org/10.1136/rmdopen-2021-002049
POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
https://doi.org/10.1136/annrheumdis-2024-eular.809
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 25 September 2023
Accepted: 25 October 2023
First Online: 20 November 2023
Declarations
:
: Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. Andrea Rubbert-Roth: Received honoraria for lectures and consulting from AbbVie, Amgen, BMS, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB. Adriana M. Kakehasi: Served as a consultant or member of a speaker’s bureau for, and has received grant/research support from, AbbVie, Amgen, Fresenius Klabi, Janssen, Eli Lilly, Pfizer, Organon, Sandoz, and UCB. Tsutomu Takeuchi: Grant/research support from AbbVie and Eisai; consulting fees from AbbVie, Astellas Pharma, Eli Lilly Japan, and Gilead Sciences; speaker/honoraria from AbbVie, Astellas Pharma, Eisai, Eli Lilly Japan, Gilead Sciences, and Pfizer Japan. Marc Schmalzing: Compensation for consulting from Chugai/Roche, Hexal/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer/Ingelheim, onkowissen.de, EUSA-Pharma, Novartis, AstraZeneca, Amgen, Medac, Lilly, and Galapagos; speaker’s fees from Novartis, AbbVie, AstraZeneca, Chugai/Roche, Janssen-Cilag, Gilead, Boehringer/Ingelheim, Mylan, Galapagos, and EUSA-Pharma; travel grants from Chugai/Roche, Boehringer/Ingelheim, Celgene, Medac, UCB, Mylan, and Galapagos. Hannah Palac: Employee of AbbVie and may hold stock or stock options. Derek Coombs: Employee of AbbVie and may hold stock or stock options. Jianzhong Liu: Employee of AbbVie at time of study and has since retired. May hold stock or stock options in Abbvie. Samuel I. Anyanwu: Employee of AbbVie and may hold stock or stock options. Ralph Lippe: Employee of AbbVie and may hold stock or stock options. Jeffrey R. Curtis: Research grants from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Janssen, Labcorp, Lilly, Novartis, Pfizer, Sanofi/Regeneron, and UCB; consulting fees from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Janssen, Labcorp, Lilly, Novartis, Pfizer, Sanofi/Regeneron, and UCB.
: All studies were conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, applicable regulations governing clinical trial conduct, and the Declaration of Helsinki 1964 and its later amendments. The trial protocols were approved by an independent ethics committee (IEC)/institutional review board (IRB) at each study site per Good Clinical Practice (GCP). All patients provided written informed consent prior to screening.
